Transforming how bioactive molecules are made
Late Stage Stereochemical Editing to Transform the Synthesis of Bioactive Molecules
['FUNDING_OTHER'] · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · NIH-11014627
This study is exploring a new way to make important medicines that can help treat different diseases, aiming to create safer and more effective drugs for patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-11014627 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new method for creating complex molecules that are crucial for treating various human diseases. By using a technique called stereoconvergent epimerization, the researchers aim to modify the three-dimensional structure of drug candidates after they have been formed, which could lead to safer and more effective medications. This innovative approach seeks to simplify the synthesis process and enhance the properties of drugs by reducing toxicity and improving regulatory approval rates. Patients may benefit from new and improved treatments that arise from this advanced chemical synthesis.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals with conditions that require complex drug therapies, particularly those affected by diseases where current treatments have significant side effects.
Not a fit: Patients who do not require complex drug therapies or those whose conditions are adequately managed by existing medications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective medications for a range of diseases.
How similar studies have performed: Other research has shown promise in similar approaches to chemical synthesis, indicating potential for success in this novel method.
Where this research is happening
CAMBRIDGE, UNITED STATES
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WENDLANDT, ALISON — MASSACHUSETTS INSTITUTE OF TECHNOLOGY
- Study coordinator: WENDLANDT, ALISON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.